EYPT - Earnings call transcript Q4 2021 | EyePoint Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. My name is Jonathan. And I will be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Development's conference call. There will be a question-and-answer session to follow at the completion of the prepared remarks. this being that company's at advised request. be call recorded is the Please like call turn Elston, would to I now the Officer EyePoint Chief of over Pharmaceuticals. Financial George to Please go ahead.

George Elston

Officer. begin Jones, today's will all quarter full recent discuss results. and and fourth will full Commercial Chief commercial corporate Lurker, Jay With will year and Dr. the updates. recent joining you pipeline me EYP-XXXX, EyePoint results activities. and thank of Duker, Chief a financial Executive Officer; review our close on corporate momentary Nancy with And for to discuss Officer; made XXXX comment you. us Thank and Dr. Chief President on then recent conference Scott XXXX and today call on year Pharmaceuticals' financial on Nancy I Scott for quarter progress the Duker Operating developments. will developments fourth is

open we release commercial tab then development. corporate will found well the up as copy questions. and for press your Investor the on financial be as website, on our the of a We detailing A issued www.eyepointpharma.com. this results call morning, can operational the Relations Earlier release

about including today statements our plans that success developments clinical we section of which discussed and is formal of represent expectations, these These the Actual make various for Any with most statements Litigation and forward-looking only. and may we future financial in XXXX. that in the products our provisions of Securities potential remind annual our and XX-K, timelines, Reform of safe filings forward-looking various report in the and Before will as statements prospects. under on indicated the views matters of of the make future. SEC begin include Form product other Act today and SEC with differ projections regulatory candidates, harbor comments, purposes may important as I'll statements by constitute Factors results a the remarks our you from forward-looking we the our the on recent Risk those result those factors materially file Private

statements do change. forward-looking elect these representing While future, to of Chief statements if update any we Nancy Lurker, some our so obligation subsequent call we Pharmaceuticals. as these point you the to now even disclaim specifically as today. at date should turn on I'll Executive views not our any views may in Therefore, EyePoint rely to Officer over and President forward-looking of to the

Nancy Lurker

for us truly Thank you, on George. you joining for thank was an as exceptional XXXX EyePoint Good Pharmaceuticals year morning, And everyone. fronts. all

begin by me and emphasizing in we Let XXXX into momentum positive of the had XXXX. the fourth quarter have continued

for delivers with XXXX, and vorolanib patients a kinetics AMD. and viral data true Phase of for patients products a is our today's maintenance. a can combination EYP-XXXX, the first for time, of with wet completed induction lives And leader as positive and a burden that X months well every the made safety eye In This be MOA every our to wet patient DAVIO significantly who that team's other of trial a and EYP-XXXX drug release shareholders. order We in execution. revenues. a EyePoint and treatment results an benefits our efficacy supplemental our our needed which order validating molecule six year reported supplementing Durasert, runway I'd our the our long-term administered With positioned with month with ocular X Durasert EYP-XXXX, macular with longer with safety growing patients, balance patients improvement for initial exciting for a trial require Phase clinical and and commercial VEGF Prior that my of our States enrollment, based sheet, achievements EYP-XXXX is and a to like paradigm, this from with the believe goal patients continue serious to United receptor of XXXX majority X in strides transformational more paradigm, is year's of reduce three-month under to that treatment committed call pipeline our so treated great those could substantial treatment one in to new are Throughout on value up has be most intensive treatments asset, this overarching and XXXX, pipeline execute a Technology positive current is being with we new XX-day maintained greatly anti-VEGF or with create example action months kinetics. improving of period the after mechanism provides of or dosed program, are our We no anti-VEGF bringing mission, sustain potential patients six-month of to binds In providing delivered new treatment disease delivery. month. therapy. coupled our age-related from a cash to across our patients up of turning six with colleagues, interim EYP-XXXX The therapy we results, zero we innovative The the drugs. far. six-month around large for over the patients all majority potentially Presenting data a proven extending highlight every lead where traditional to the our substantial vorolanib, world. remain and business. strengthening patients term TKI to the BioErodible degeneration lead to while presented the on few months DAVIO time. majority zero disorders sustained EYP-XXXX

transform AMD important EYP-XXXX’s and ever. treatment month, last at data more We February, to the the safety in for followed Exudation XXXX eight-month potential positive continued wet with Degeneration interim Meeting. we than and Additionally, Virtual Angiogenesis paradigm up efficacy believe is

all significant and and effective of and disorder, remains eye landscape, across But effects market, and AMD approximately category. treatment accounting treatment need medications is FDA-approved to treatment AMD for XX% wet the we in devastating see unmet As an longer compliance potentially the especially a duration Wet patients AMD continue on the challenge ongoing thus, and related despite physicians. long-term adherence blindness. for safe serious

we we're for far execution drug to potential inflammation technology team showed we with possible. the delivery also far. Jay that sustained commitment entire XX-month as XXXX. quickly XXXX, and later positive in organization's December no the C initiate are demonstrated and in the demonstrate U.S. the FDA. second aim for And X what well technology patients. and pleased X-month our interim EyePoint with and in As the in is look on discuss expect more safety reach to combined milestone path confident the patients this with the our EyePoint this will to emphasizes DAVIO to leader incredibly promising at efforts the to AMD impressive In trial The half delivery. six innovative intra-Phase to bring meeting with detail EYP-XXXX efficacy at EYP-XXXX study by data And results, positive so eyes quarter call, data thus significant X team's Phase through as we the wet third as many our first in of results the in follow-up concluded eight-month Type of Durasert becoming right the we can as dedication results informative accomplish XXXX, the a ocular which of

indications in for forward wet of on to EYP-XXXX providing diabetic for activities all future second advancing trial of potential for Phase a indications and an with this study expanding non-proliferative in months update come. half with retinopathy to year. AMD, to or X in X additional We a of NPDR, addition beginning treatment Phase look EYP-XXXX the you the In forward look to we to this clinical EYP-XXXX paradigm-changing

commercial Turning to product our pipeline.

are We product XX% the increase XXXX net for report customer demand quarter products to of XXXX. and fourth to in compared our revenue pleased a both in very commercial record

since ImprimisRx, bringing We been to Additionally, we approved our products commercial of to internally despite to more our need the August ophthalmolic in continuing with able patients while forward expanded business a program efforts pipeline focus pandemic. we've commercial transformative our as to therapies. XXXX on commercial strong grow alliance which our been look partnership has ongoing U.S. our

year As million, with and first you'll an as we on hear on million exceptional completed from $XXX and to over investments financially the successfully the $XXX also year offerings, two end upsized follow George raising of later XXXX on, our allowing us during hand. was offerings fourth cash equity quarters,

motivated And turn clinical, will the Pine grow we committed Officer. of so responsible continue and well Development Pine and the continue leadership to another made our update organization we XXXX EYP-XXXX EyePoint EyePoint's announce In ocular as are commercial over the on our year, very to our pipeline development to drug Corporate last Finally, this to XX year were to Duker, and team. execute Strategy Earlier thrilled Chief to program, almost Dr. of years excited overseeing for lead I'll for company's We've advance multiple be company's are and future operational EyePoint brings Pharmaceuticals. to productive and to on our and our strategy role, business appointment this in call year. of Mr. rewarding the Pharmaceuticals delivery. experience have Michael board exciting and to financial pleased Chief success want on business Jay? sustained and all as continue we other fantastic we're Operating during this to promises initiatives. for business. also of now we catalysts evolution. him to sincerely Jay He tremendous the strengthen provide an Officer, time Pharmaceuticals. in I date. our thank progress team development to at And to And clinical strategy. as EyePoint be

Jay Duker

good And morning, Nancy. you, everyone. Thank

journey. what I point this want in begin, I Before is to EyePoint's an reiterate exciting

pipeline we to of the Phase team therapy being multiple clinical as for Nancy sustained-release care positioned following Our induction catalysts with execute on pleased our quite macular anti-VEGF. this therapy advance X for stated year pipeline. a trial delivery lead our And age-related degeneration, standard we're as an program, DAVIO results as of maintenance our studied with treatment investigational EYP-XXXX, the earlier, wet is

teams AMD. have the us to And trial. for or sustain the AMD of clinical interval efficacy positive and wet been patient’s on this highly results and successfully about EyePoint's safety is majority give regulatory wet profile six in X up and X-month Phase to increased focused confidence efficacy months recent treatment differentiated tolerability data executing EYP-XXXX's longer. goal Our safety,

Durasert with track with we form, and the record the anti-VEGF been to sustained mechanism with true proven thousands for retinal the differentiated bioerodable as seen consistent release of treatment the with of less of safely EYP-XXXX administered that technology in zero-order described and the molecule Thus, much kinetic across just a drug patients' safety, can bolster change small PDGF. use delivery. combines differentiated bioerodable order VEGF its and from its a efficacy current medication antibody and kinase four zero paradigm of we are like is I'd of has I with have the alternatives to our Technology review from tyrosine current sustained antibody system. the a trial Durasert products. so results the drug formulation of bind isoforms blocking of data, ligands. potentially differentiation EYP-XXXX. far different today. kinetics. touch market U.S. to Durasert steady FDA-approved a as the These In allows delivery this anti-VEGFs the Durasert confidence has Durasert the safety landscape. all fragment coupled non-erodible tolerability of Vorolanib this well VEGF form molecule DAVIO Before to best-in-class vorolanib, approach in binds EYP-XXXX on receptors our on delivery bioerodible to a This action, inhibitor. VEGF used in eyes And burdensome Durasert release drug technology

Ophthalmology previously of XX Turning four study All label care treated escalation and was reinjection patients enrolled were with updated is enrolled year No performed now standard We employed. data therapy. supplementation six-month eight-month dose a across the Angiogenesis data was February to the in Academy our DAVIO study recently and of safety with wet of Meeting. at the DAVIO the Phase groups. meeting trial this American positive standard And DAVIO trial open AMD that efficacy XXXX year. with dose during last with the November criteria for anti-VEGF interim standard the in of more X drug this of study. care of anti-VEGF Virtual reported patients at

we've results interim the with far. pleased observed quite are so We

over patients, with months months, and to reduction durability months. a eight seen nine free as of burden for up efficacy impressive XX% as in well we've Importantly, six treatment free at XX% XX% six at to patient’s and months significant reduction supplemental up anti-VEGF reduction XX% and

safety central ETDRS in letters thickness adverse of occurrence saw updated on with eight-month release, Additionally, measured ocular the subfield inflammation and Furthermore, OCT XX the ocular no positive Furthermore, of was data into the or serious enter approximately drug acuity no no highlighted visual we no stable visual [ph], best endocomitis minus related acuity six-month X no showing as migration with corrected and in demonstrated reported. of thickness dose OCT of implant detachments, toxicity, any limiting data eight-month chamber no retinal as subfield plus systemic significant events cases SAEs. central data by microns.

the profile as potential AMD landscape. treatment six in Taken early clinical treatment data a together, these -month differentiated EYP-XXXX’s wet represent promising

as a we for The Phase or corrected Nancy visual treated assigned or one two of OCT, approximately enroll thickness quarter X in approximately efficacy X safety. wet study previously EYP-XXXX milligrams change in change AMD is of plan As controlled mentioned, by best and trial X EYP-XXXX wet to to anti-VEGF of endpoint the of aflibercept-controlled supplemental acuity patients to randomly and this randomized overall of central expected doses time AMD Phase in with either first to XXX milligrams X third initiate year. subfield measured

the X anticipate XXXX. second interim from Looking data trial ahead, sharing this we of half six-month in Phase

a retinopathy trial the EYP-XXXX of the of for working potential the trial In diabetic retinal disorders, severe other second this initiation, to application also we year, EYP-XXXX We eye treatment initiate non-proliferative of non-proliferative exploring in vein Phase towards of and are half occlusion. including diabetic X clinical plan renopathy.

to commercial over update. year rapidly updates continue as call these to Scott? will Commercial will on Officer, our Scott Jones, now indications the clinical throughout pipeline additional advances. the I We provide turn growing the Chief for

Scott Jones

to to report year for you, doctors' commercial We're a in previously products our compared product We're Thank and and XXXX. record fourth of net businesses including delayed see for XXXX million of commercial and patients pleased revenue, their excited Jay. $XX.X procedures. with offices a the demand both schedule increase return strong their quarter to of surgeries customer our XX% to

NDA, quarters of Customer our to and in units and DEXYCU strong from $X.X was respectively Our for to million alliance QX QX and with DEXYCU activities the for approximately for when look you of demand. would to XXX products. and Pharmaceuticals that on a support August DEXYCU distribution physicians and attribute providing the remained all call last all patients were to U.S. rolled -- come. to expand on. like strong, YUTIQ terms of net recognition, needle, XXXX, in use now to team product our and experience by forward doctors our for U.S. customer out markets. our during our pleased the improved patients. also units a procedural commercial incredibly visits consistently quarter our to year EyePoint full revenue rely offices gains YUTIQ they DEXYCU part of updating and George? majority result team organization. $X.X We compared EyePoint's proposition and that requires turn marketing we our a revenues Customer established retain for to for partner absorb was our We in the physicians commercial that revenue the XXXX the a approximately for partnership review will demand I the ImprimisRx an units financials. sales million, continued XXXX DEXYCU of key stemmed delivery and customer siliconized in of DEXYCU alliance product's their improving the respectively. past value both XX,XXX for thank demand demand the amended commercial sustained was our to pleased YUTIQ year commercial responsibility like collaboration the of Customer across We're in all and this We'd for over EyePoint's unique of expanded announced with ImprimisRx. demand system to fewer Under agreement, of of patients XX,XXX presence provide made the each XXX commercial and DEXYCU. doctor's businesses. responsibility mission and fourth commercial of progress the units original and manufacturing we've George products

George Elston

Scott. you, Thank

were a on an ended XX, the the quarter. the in release public we begin, roll equity for for will year offering As future with full and year. press to months focused review out XXXX, last be the over million, in proceeds three issued capital pipeline additional for strategically comments our to To raised of high The growth. November morning, funds pursue December financial provide $XXX.X bringing results gross upsized XXXX, this with financings my level included today million opportunities company's underwritten executed and strategy total us $XXX potential the

period Net revenue December to ended ended in million Non-operating and XX, the to totaled and share $X.XX in increase December primarily revenues product ended a December for $XX.X or compared quarter For December product increase from $X.X year $X expenses the loss a the net compared to December for share million increase per compared to million a expense, XX, revenue $XX.X increase sales Net $XX.X XX, expense and XXXX. Operating of net million in million XX, and ended million of XXXX total a the the XXXX. XXXX, million versus G&A $XX.X quarter in million from period. of This $XX.X $X.X in was in collaborations the fiscal revenue the ended prior net $X.X royalties in quarter the sales. XXXX, a net XXXX for million. the $X.X XX, per quarter million $X.X increase totaled corresponding expense quarter for compared year $XX.X was $X.X million R&D to million for loss million was cost totaled expense, million due million prior $X.X marketing year or period. $X.XX was $X.X net

compared in XX, December million $X.X XX, $XXX.X December or million the $XX.X $XX.X prior $X.XX was the December for $XX.X a R&D Net increase December XX, XX, was royalties million an $XX.X expense Total period. net increase $XX.X on ended totaled year year was the a $XX.X totaled a XXXX. full $XX.X to marketing million for December per net investments and in for G&A XX, in XXXX $X.X collaborations increase to revenue million sales and in versus $X.XX XXXX expense, full ended prior full corresponding in to ended million. revenue $XX.X net revenues due period. revenue the net compared to for million, sales per year and ended increase December was expense. and expense, December XXXX. year million million ended largely compared XX, million year of compared in $X.X million $X.X product share to XXXX the totaled cost year year million in million a loss December year million share increase $XX.X in to $XX.X And XX, This Non-operating the the Cash $X.X full million. net million in on of or from for of loss XXXX. full compared the period Net full XXXX, Turning $XX.X the Operating expenses ended totaled XXXX, XXXX. product XX, million to

the fund in progress call hand product inflection XX, advance expect our I value cash of and conclusion, morning, and the pleased to pipeline very you half questions. planned well points. turn us our second are XXXX investments December operations enable cash the EyePoint's on this We sales expected Thank our capitalized operator into now will all for current for with over product XXXX. listening are key and from on to XXXX inflows In to the to much we and and

Operator

Jennifer of Our Certainly. from Cantor Fitzgerald. [Operator from line question comes the Kim Instructions] first

Your please? question

Jennifer Kim

my everyone. few And questions. earnings. Hey, have on really some I progress amazing your since Thanks Good taking congrats morning. for here. last questions a

include Phase And shortfalls And half the that next what are the could some second from data of the of year. still like seen what is wondering trial of Thanks. then competitors the for first my year? guys? quarter your vein, second for that what with TKI you thoughts some does on potential on X of on a up runway, cash I'm First, competitors I your come Kodiak mean ahead guess, are question recent similar we've thoughts that in and set RVO your this does --

Nancy Lurker

Jennifer, it's Nancy.

Okay.

said Yeah, that that, coming questions. competitor is, then So will I'm or then the data TKIs and data how their I and the thoughts cash, believe I George One recent you -- up, last heard Kodiak other on our which readouts shortfalls. is three And correct? might on if handle.

data this Let I me give do. and patients in. get like want competitors. It's and be generally look a can then and physicians speaking, been that don't I for we It's Look, if to quick a insights very you have opine be tough obviously I to it's -- in appropriate; is into landscape. is a, really more at what's difficult our it a happening, Jay depth. say careful. they just, b, would tough don't to certainly not overview, want I on investigators think field and unfortunately just Because,

delivery or just occur APIs, And companies struggling you're just active with efficacy they which to dropouts they're have drug can't end drugs, profiles technology or just so able hit safe they're unfortunately, not -- points. are either with either their seeing

X results. So you're starting field good had really whittle to Obviously, to down. this see Phase very start we

nine-month good. and really to Our data continue look eight will

probably the community fewer for but it's for I that's us, So Ultimately, have think competitors. overall. don't good we good

to Look, other the TKIs. readout. to we forward their look As

going tyrosine you'll as readout, you're more that kinase think is what I inhibitor the TKIs to how start see validated is to target. see

delivered study vorolanib wet And that That efficacy efficacy confirmed partner wet though. AMD was it AMD TKI just in AMD. our showed seen then we've ocularly. which oral with with study not did, certainly, obviously, DAVIO the wet with our we announced, oral an studies, Now only in

others, If issue. would say I'll them, far. did more even problem Graybug a so at they with their results have you the shown Ocular, both was And their name delivery I good look Clearside, drug TKI

that again, is has have to think want for be to terrific validated, I been just action only target on because give and you mechanisms which patients the So target. of one to to able targets physicians not continue use different

Now at But level. again, if of the effects all large those. differentials the know level, look you molecules, have as positive ligand certainly, much they you there. receptor hints don't broader TKIs, attach there's to attach they We might some some The a kinase know and at cover the number of the that you receptors.

have that physicians patients think different good can targets I it's for use. So that we

TKI And if I'm quite so targets add the to far, ask look going that. to good. to Jay wants anything

Jay Duker

and we're to is all Nancy, it or really here the efficacy thread for, end. longevity EYLEA What hi, respect our Faricimab. EYP-XXXXlooking isn't But next high at of do really summarized patients. safety to or the with next to what our Well, trying well you the really it the improved be needle Jennifer. for

-- months two. And a looking to maybe but less up even or able We and longer. our who month than, less frequently drug taking majority frequency the say maintenance be unable a or them really therapy to patients at less to X treated are treat them every hopefully taking of being frequently much are stable,

in know patients in learnings very the space. while you Kodiak are -- as is And Phase So failure There choose well practitioners all some X our the pivotal this trial. community. a disappointing how in as again, we for us that may big and to is again, design for

is active And improve things really probably competitors fine and it us our to patients. forward all so having pushes for

was The other question, I financial. think,

George Elston

Jennifer. here, for thanks Yeah. in. Hi, dialing George

at RVO our initiation and guidance year. second So retinopathy on some the -- into way release sometime the morning. three of our wanted process wet premise that's that managed hand the AMD is diabetic business does non-proliferative point AMD, of -- with always next And reads in we X XXXX least study this half second X we've at on cash have in our today -- year studies we've studies the include the and the on cash Phase one year, updated which that next earnings then when out. half wet of yes, And we -- to

Jennifer Kim

sneak more particularly X this in quarter? anything I more If is sustainable? Thanks. up Was of for there YUTIQ Was Scott. Or a drove this DEXYCU that and could demand pent Okay. sales this demand? onetime Thanks.

Scott Jones

their certainly in the especially for you, there all trying patients market question. the know in the hope the Obviously, seasonality ophthalmology a end some the Thank of Jennifer that of And procedures sustainable. demand the to is get as we is market, the reset medicare We benefits where year. at are for beginning the year.

pandemic. Certainly, that that we've And moving But we consistent growth that, will think we forward. seen hope. our the despite is certainly see seasonality. curve pretty some do So a continue

Jennifer Kim

Thanks Okay, great. everyone.

Operator

you. Thank

next from Our of the Yordanov question line Cowen. Georgi comes from

Your question please?

Georgi Yordanov

congratulations questions. guys. taking for And progress. much Hey, so on our Thank you all the

options explain this up we disclosure And start the on especially do on result? how question. you acting some who also, observations then of presence Phase talk vision you these fluctuating And XXXX? had patients the follow-up think are longer could that multiple the for medical market? practice, you've fluid. How from observations about start, follow longer saw despite to to there the competitive you period just having maybe some Specifically, initial change some the could trial So X do subretinal improvement of once of

the could of things to there their AMD of TKI. sizable thoughts responders we VEGF the a this of was from responders from it you see subset thought is wet patients just AMD? was population on that And we data, wet a broader potential if Maybe that really seem that size really hear patient interesting this. of who and of a possible kind and VEGF did such as found that like if that can like confirmation your that One data benefit are from inadequate in inadequate it mechanism a was

George Elston

I'll And try and learnings you questions. trial. Well, Phase the to those start asked from X just our top about excellent are at

all First that really of no this at very pleased were we're safety there all, very clear signals it's in space. because

you have I like. and everybody, so your months would to an quite looks matter doesn't in XX If it look close what efficacy a don't things getting good NF-XX safety, good. follow-up, And so with say, far

Our are, and six But supplemental primarily we able be AMD again, means, or use via drug our VEGF a patients other one-to-one marker appear important is there known months for percentage be activity. of Fluid without significant is that for for visual learnings longer with not And wet to We've that any anti-VEGF. maintained relationship. maintained acuity. years. there's a as a to fluid OCT

You that thickness way and it's the in in vision bit is back OCT show retinal the X.X, subretinal well. about correlation good, And which can acuity anatomy not anti-VEGF coefficient little in Stability between stability great. earliest with means and have accomplish go only trying visual we're to we patients all with who EYP-XXXX. is in a of what fluid see pretty study

EYLEA from dose XX% EYLEA treated of have patients even when fluid, the that the study also We current still Regeneron of heard high dose recent monthly.

may it's to there out all patients there's fluid, go get patients So okay. just subretinal little that away. our a if we a actually the sliver lot But strive dry. of And that of can't fluid get to be

So we're necessarily do again, is not what better. trying to drive

We are longer. stable to patients keep trying

second was learnings --- from about Your question

Nancy Lurker

Inadequate VEGF.

George Elston

Yeah.

visual given at as not data It when looking EYLEA OCT at we're early drug acuity asking as it's for good given know just in a And was really does OCT think I really were results. Kodiak’s the about hard slide the they you at deck releases, look sure. you're But to like press specifically, looking improving is. monthly. are So again, that in Kodiak

I Now do as how it not drug be long-term is that's maintained another long-term. naive patients that's looked like there not say did overall the XX%, a a really their tested well data. That's the tested And with percentage of XX% good They But not that drug. But over patients well certain EYLEA. they as to that can't do it they how was it. interpret all-comers. percentage, as the problem could

you fluid of Others, some still the it's to them then And is, lot trying number who a only XXXX. available. with, with along, help. those is there. there say free we're do months sometimes those can with products perhaps go more probably for that's who patients patients with patients the can a they one and are with have all a can interval trouble go XX% label and once going And of are to minority they that's treat identify it in the have And from the can patients to go a to the are them you load. out So try can that. you drying a one long want not -- you're patient. well fluid. in and treat the dry X do time, And ones to agent the that's patient our VEGF yeah. direct But the what to longer anti-VEGFs longer well drug the XX%-XX%, We've longer. is really monthly determinant again, our hopefully, of of to And physicians than up is going get who these we or the current to to the going a even and months known goals who high some need drug, have best the three or

Nancy Lurker

to a the these delivery acting as just could talked of change benefit about, patients get not is can to it's your we're therapies and a longer going believe emphasize. like and to that I'm the see to further comment me to we've months. but paradigm, just every if to then that the want treatment add patients will things on question let well, only on we trying little Jay other which -- different one this, on these potentially six board back that about action. And EYP-XXXX, thinking I Georgi, bit extended That's from you where continue mechanism have of

more protective But than kinase supplemental a have term. longer to providing others. you Some maintenance continue occasionally, some from of inhibitor, molecule these patients support EYP-XXXX might hopefully on therapy board, the tyrosine that large antibody need

therapy if has you relatively or it's on patient of be think to dry comment. you not as be majority you is patients, can can't supplemental or But of might it dry going cases, in board -- as In if the we have be either And will the think needed they on continue the see provide get. a wants maintained. drug a able we to this and then he patients again, do maintained. to to I'm drug. Jay to majority So put been fact, after be EYP-XXXX back some that treated patient

Jay Duker

that common. other is obviously, medicine, of summarized quite pressure, think Yeah. at in And this for well. really No, it example. areas blood high Look I

still are for of even seeing effective goal. And through with less That's top But analogies a hopefully, different can a patients schedule drug drug. way a break so add a a of of methods fluid, got on maintain onerous patients of to on that, you safe on were where but some the hopefully an if they little lot with before. and they're as there a lot with of out much the what at you advantage the action that there another

George Elston

Thank you congratulations really the was all progress. on great. And so much. That again,

Nancy Lurker

you. Thank

Operator

Your next comes Guggenheim. Suneja the from line of from question Yatin

Your question please?

Eddie Hickman

Yes. questions. Hi. quarter. and taking the Yatin. congrats guys on my you is for This on morning Thank Eddie Good for

before the you about to proposed six six-month you then same including in remind for and a selection DAVIO, you the an if avoiding to arm how put goal and us due Phase adding is interval the other any thinking a follow-up, as device of thinking few device just earlier you're Can making non-responders? studies And injection indications? as from Just DAVIO? patient months? And techniques changes where across potential like you're in learnings Thanks. all in the you in me. any where are procedural are X And about did there future using

George Elston

great So questions. Thank you.

First office a to XX a injection we needle, that anesthesia. of gauge is three with all, inserts inject to in remind enrolled delivered It from everybody, single and a a DAVIO. injection. with drug just is we've bit And to our yes, intravitreally in learned local the even able up XX quite the patients we single are

that three the fact every We And injection the specialists it's dose I be certainly obviously bolus medium three approximately what into we as four the the That's do that, intervals, interval retina every believe opposed disclosure the patients. than liquid, inserts We the drug injected of not longer dose a change standard I Phase In may that of saying So our kind X can in full to from From want to would we inserts. milligrams, with months. be which can the few in say, months we successfully really clearly that are think the only, to. at than likely even spot an milligrams, would used AMD retina takes months. again, very, six need for injecting for the months. the would out any seconds DAVIO, less we XX% four got to high specialists a X is wet a go months. and inserts. perspective very with X In sweet some every to six is quick that eye. for X so rapidly don't look educate do is Phase X The trial two our approximately investigators that on study

again, retina, what therapy. that we in call -- this So is -- this individualized

get I version if what that by it the being a from is think really used every differentiated and go monthly of kind treatment of other will or be and to. we're both mechanism and how drug out month injecting which But we long there in have of would a I if label think doctors we not action delivery they're can used, what figure the our differentiated. that patients modified out system

injections look the with lot the let the think going to going we're that we we're data in So of and potential a that. again, out And drive to have we future. where I the market go schedules for

Eddie Hickman

might Thanks. And you you how just about can then the or antigen talk criteria enriching…? be

George Elston

Yeah.

-- required were at clearly XX patients there data, anti-VEGF patients, our who one. month look we you if supplemental X X had the So at Phase a

injection to fluid standard in that of on care previously zero. Now had it didn't wet no have or everybody, week in everyone got They XXXX. coming a treated But about AMD. study And they had just could later, matter. a day got remind everybody fluid,

if XX had that was or So standard five after new they of at care fluid of month microns weeks a injection. more one,

aren't investigators of of DAVIO that well Phase with with care. drug. are And tells standard put evidence trial doing weren't going And XXXX, our not again, eyes, a into patients that I it's that towards to what They're not their just they X patients think they us So logical end that trial put are doing weren't those well that. I the going those is to assume well who doing best skewed to patients a obviously are well. who in new of think doing

didn't, of drug. going patients doing probably are who been who our care And Those standard it still in who of like failing microns XXX my to do of not have are previously mind, well well in analysis So the who CST. but have certainly they're did also. more in and than patients looks treated as

well, that. Well, maybe CST. board, standard two argue, or months, treat for point. of paradigm microns still three monthly XXXX have on you treated the on them with they're But true. maybe XXX that's if of along for, could at And board that you approval care being FDA could you Now be and may not put we're with this that every going

that we who had those observation So despite patients also early treatment I also. significant in made intraretinal patients that the as still fluid, retreatment required anti-VEGF previous explained,

patients that going more doing weren't get a there patient So that DAVIO, trial, population AMD for wet in AMD we as skewed are towards out of which opposed the well. more next was got this with wet what the think we're of I excluding along I to broader the who fashion, reflects we population timing to much think them. In diagnosis

Eddie Hickman

Thank you.

Operator

you. Thank

Chen of Wainwright. Your Yi from next question from H.C. line the comes

please? question Your

Yi Chen

enough Thank that did questions. about you supplemental six before will to have patients a world of XX% months. Thank anti-VEGF even will a doctors label Could And perspective? commercial a my whether says for in months? patients six be taking you. maintained not of from think on require months patients six comment though good these still you see to Do real the practice, if you up up product XX% could

George Elston

Yeah.

for that, that we these diseases how see the specialists So can into excellent questions. we in treatments mentality the of think the of look And new I kind past. retina adopted and

are. be if XX% -- longer, go to XX% six the commercial opportunity, success of all a a eyes of months safe, ahead So can those sudden, effective we going drug Because and greater your and terrific time every is of rate if we XX% have can have identify a XX%. who especially tolerated we or fantastic, than

to just the going aren't ones will. patients who necessarily the injections out ask going on You're to to well, do pick who do the not doctors

retina specialists course, figured it out. Of

than go out think take safe do initiate We out the necessarily We will new do try older the we we and and monthly. see how don't work on drug them we will and if often, And seems and often try drugs? we'll better watch them is we on patients label. best So who the them to we it, new drug.

drug, any going monthly for be a we while So think have don't different that's to don't I XXXX.

and with they to those in XX%-XX%-XX% or think patients in on might do I well. recurrent without six of which drop to are patients those we They'll every try patients six who months case fluid the get retina identify likely vision, community go who They'll terrific. help XXXX, months. continue

so they'll think months I I without the all. No, go to, let at Now think a beginning at visit. don't them six

monitor fellow AMD. a to the if widely wet Although going acting be might if think even to for I by want home. more the a Probably want months? home to patients to they convert them, to patient The to differently. we're nice And adjunct or eight monitor want little wet that But in not see help I may eye the every be six OCT carefully. I available a beginning, to at see these is patients at eye the certainly, end, not. fellow watch AMD

year, still injection least an will require six at observed months. patients these only be think several they if eight times I every a even to

even on who those seven five may Now probably might XXXX be weeks, And who to trial, six or the the group months every who another or ones with there'll weeks, never EYLEA well. four the patients the LUCENTIS try nine [indiscernible] fluid. benefit perhaps from weeks. at Because months. one, at into required we see and extend supplemental patients, than treated and a we be are study every Those those anti-VEGF we patients more or up of months of every time that, several required as had to four based DAVIO another every are

So every or three rate or we cut months. four six their weeks injection to so from every

be to benefit a And patients that's going so well. to those as

period, long-term So a different be And even beneficial, a especially be before of think not if they MOA. have supplement have, ligand Walker. that they certain patients on adding and still mind ligand another piece rescue an that specialists because anti-VEGF I there's six-month the as do a be it of may knowing will It's to there's early board. going going require to mix retina action. blocker a I it's another It's or think to benefit a that well, different

be another result what worried and to miss visit, sick visits in? as one may have if a not we vision. two get they're they as and if if or what in So So the drop get What their get they hospital? they pandemic that missed going can't in a significant

Yi Chen

update XX? Second question, an YUTIQ could you on give us

Nancy Lurker

Yeah.

continuing time. some to we're to continuing are which patients. enroll we now, And to enrollment right So taking the the study. complete, monitor And waiting is for we're

Yi Chen

X? many the How be will Phase enrolled for patients

Nancy Lurker

-- I think for we aimed

George Elston

XX.

Nancy Lurker

That's correct, XX.

Yi Chen

Okay.

in X second half the results will study report this Phase of the So year?

Nancy Lurker

was never plan. That No. the

George Elston

No, Remember, it's that. we haven't an guided disease. orphan on

Nancy Lurker

These said, patients find again, to are as find harder just George because, to and locate disease. orphan an hard a it's little exactly. It's Right.

George Elston

treatments there, are XX good currently [ph]. there And our out including YUTIQ

Yi Chen

could lastly, the YUTIQ general any provide of you DEXYCU expect And for you for for to comments trend XXXX? regarding prescriptions and Okay.

Nancy Lurker

I just forward turn actually this we give want to going Scott. don't I'm over guidance. to caution, to

the that of now. environment So sort I'll just we're in let right operating Scott comment on general

Scott Jones

We prescriptions relative a Thanks say expect we what to specifically, I that had expansion said, are customer seeing expect seeing we with our of and XXXX. say, customer And to And our that guidance as And the But is we're receive segment. retina XXXX. can I continue to YUTIQ of for an specifically, expansion base Nancy specific not the the in of the that we're to would to number we provide in start see base. going question. occur. expansion XX% I'll within

uveitis So not traditional of just business. the the segment

So that continue I that think the would expanding certainly believe to expect to doing XXXX. and lead market in us we so we're

increase we've in seen an side, customer we've base. DEXYCU the our On -- again,

at More of surgery of ambulatory the customer centers. base, seeing each those utilization we're importantly, one within an expansion that

center So ImprimisRx partner with did certainly XXXX. And would number see per increase that trend our surgery of XXXX. commercial in to continue the like and we into units ambulatory

Yi Chen

Okay. Thank you.

Operator

Thank you.

the from Laidlaw. Jen of comes question next Yale from Our line

Your question please?

Yale Jen

one, And The number Thanks XXXX for which the in start fourth quarter significantly anticipate questions. time? that grow going quarter-over-quarter. a each for just SG&A events the for seems taking Good to occur to quarter. to or that morning. is some housekeeping Should be a I'm at that quick we with base simply onetime

George Elston

Yeah.

that's I think run-rate. a base probably good

organization not We IP well. have the invested but just across as our,

probably your looking So I'm models. up I would to you on with look two you're just happy blend to if follow quarters, the

Yale Jen

quarter. is in are start What you question guys going complete know second gating guys before third the you formally start the that Phase factors And to wet study X Sure. the for AMD trial? currently to I

George Elston

packaging a we trial. a distribution need initiate things lot kind done to have already the manufacturing, and that be of drug, of And of behind things there's so Well, scene like to the accomplished. which

which The CRO, have drugs has by to be the then directly study, site be already can to the the going. to protocols the things we've agree get then a their we be contact and in IRBs, approved sites shipped choose accomplished. sites, to CRO to the to have You need need to

-- So patient a complicated Again, I'll get the that nice enrolled of again, in companies audience running. these and all a do in our May. all was And very last remind studies all of in pace. just last there's is it's -- dance that DAVIO up moving it to that

plans months the along Phase only to are X the was that ago. November. And so initiate just six And trial. we with well we And months about got four in results

out the a that bit pleased with the X And So sites more takes We're We're interest aiming pleased of of sites have to in trial. we're Phase the sites had all for really trial choice really CRO. our multiples we there. trial. of a this time. with Obviously, this little size, XX

on gating parallel. So that remain as third there's are occurring thing. that, confident no But start today, all quarter track. in one I These of is

Yale Jen

maybe is there's your medical is recent thoughts reporting Great. there impact of the last any terms question believe, And here development? What in think on Okay. do XXXX meetings, of -- a my at the the that I that? data. about EYLEA you And X-milligram

George Elston

Yeah.

that's us, But that induced data to is be if for there maybe doctors appear But we'd patients dose. it to us. Faricimab, it's it's a out competitor give significant. on to think better, didn't assurance order that's it's does with retina even high-dose It them visual like agnostic drive I don't to when who appear get better the retina the acuity. one. We're EYLEA long-term drives or to feel ocular is with see again, good zero to we not that as they and step that drug. board. look, It in appear XXXX a that can safety longevity it kinetics the There were interesting anti-VEGF Again, Once safe seen is be whether a EYLEA, in that. to can it safe. regular dose did in of regular the as KSI’s the number So weren't to AEs couple is the high provide

terrific. we to conjunction would drug. space to I our the be help anything that in going yeah, nicely very welcome drying better, is if with that's So patients work think in And this effect

Yale Jen

maybe And in, Great. you what squeeze up just Okay. just just have more said. follow one

any on therapy initiating do long how treatments. the the depends think guide but the start patient maintenance -- could therapy Or you In obviously, initial how think factors? you when the your after you induction terms do of that? can maintenance Was there potentially long it patients,

George Elston

Yeah.

say, on as and And whole and we're that's about questions answer XXXX of getting to on which hat it. approved focused population again, how a really like works put good I'd But FDA really to in my can investigator the I patient give quickly there's lot as when question. drug possible. a clinical So

retina will test work as treatment, the going way. of your plans to have ways, in Because obvious some approval have wait i.e., that irrelevant. going work to, yes, in some the I kind clinical maintenance it. either are community to probably one those as FDA think, occurs. until if answer as is patients. well drug to we we again Eventually, is, you And or questions And is, we But it's no the will we it whether in immediate test do of naive are

As long or of current majority that without drugs as something the out six we -- which go offer patients. ability the longer another months the offer, is of in to shot none

Yale Jen

a look Okay. soon. you Great. again, on the forward start congrats And guys That's very, very progress. helpful. I to trial

Nancy Lurker

Thanks, Yale.

George Elston

questions. Thank for you the

Operator

today's does you. conference. the today's you, participation. well your as and for session Thank of as This ladies Thank question-and-answer conclude gentlemen program

Good now day. may disconnect. You

EyePoint Pharmaceuticals (EYPT) 3 Mar 222021 Q4 Earnings call transcript